BDCare and Alexion, AstraZeneca Rare Disease invite us to the online conference “El potencial de la Intel·ligència Artificial en el diagnòstic de les Malalties Minoritàries (Artificial Intelligence’s potential to diagnose rare diseases)” as a part of the Barcelona Health Hub (BHH) Summit that will be held on the 28th of October from 12 to 12:45 p.m.
Digitalization is an omnipresent reality, and the use of personalised medical solutions, such as telemedicine or Artificial Intelligence (AI) based devices is growing. Let’s explore how technology can affect “The Patient Journey to the Future”, a key theme of the first BHH summit.
BDCare is developing a technological solution that uses Artificial Intelligence to diagnose rare diseases. The first disease this will be applied to is Lysosomal Acid Lipase Deficiency (LALD), an ultra-rare disease that affects 1 out of 40,000/300,000 people. Alexion is the sponsor of this solution.
In the conference, Leticia Beleta, General Manager Iberia, Alexion, AstraZeneca Rare Disease, María Luisa Martínez Triguero, clinical director of Servei d’Anàlisis Clínics of Hospital La Fe from València and collanorator of the BDCare project for the diagnosis of rare diseases , LALD (Lysosomal Acid Lipase Deficiency) and Francesc Cayuela, founder and CEO of BDCare Research will discuss this solution that intends to revolutionise the world of rare disease diagnosis.
BDCare is a technology company from Universitat Autònoma de Barcelona (UAB) located in Parc de Recerca UAB (PRUAB) that specialises in big data and artificial intelligence focused on health and rare diseases.
You can access the virtual room here. You don’t need to sign up.